Search
Search
About
Log in
Join
Experiences with
Ledipasvir / Sofosbuvir
Posts
Communities
45 public posts
Filter results
Gilead's Sofosbuvir + Velpatasvir Combo Shows Good Results in Phase 3 Trials
http://hivandhepatitis.org/hcv-treatment/experimental-hcv-drugs/5392-gileads-sofosbuvir-velpatasvir-combo-shows-good-results-in-phase-3-trials
http://hivandhepatitis.org/hcv-treatment/experimental-hcv-drugs/5392-gileads-sofosbuvir-velpatasvir-combo-shows-good-results-in-phase-3-trials
kcohen
in
HFI Connect - Hepatitis
9 years ago
Veterans Affairs Gets $500M in Emergency Hepatitis C Funding
The new influx of VA funding, which was approved by both Congress and President Obama, can be used to cover Gilead Science’s Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
) treatments, as well as AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) for eligible veterans.
The new influx of VA funding, which was approved by both Congress and President Obama, can be used to cover Gilead Science’s Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
) treatments, as well as AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) for eligible veterans.
kcohen
in
HFI Connect - Hepatitis
9 years ago
Achieving SVR can lessen economic impact of HCV, save $3 billion
The treatment of choice was Harvoni (
ledipasvir
/
sofosbuvir
, Gilead Sciences). Cost of total work hours lost per patient was calculated using publicly available country-specific data that included working hours per day, working days per year and labor costs.
The treatment of choice was Harvoni (
ledipasvir
/
sofosbuvir
, Gilead Sciences). Cost of total work hours lost per patient was calculated using publicly available country-specific data that included working hours per day, working days per year and labor costs.
kcohen
in
HFI Connect - Hepatitis
9 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Your role in hepatitis C treatment
While it’s encouraging that a new class of prescription medications can cure hepatitis C, the high prices of the drugs are creating a quandary for healthcare stakeholders. The first new drug, sofosbuvir, earned FDA approval in late 2013 and carried a price tag of $84,000 for a course of treatment. “
While it’s encouraging that a new class of prescription medications can cure hepatitis C, the high prices of the drugs are creating a quandary for healthcare stakeholders. The first new drug, sofosbuvir, earned FDA approval in late 2013 and carried a price tag of $84,000 for a course of treatment. “
kcohen
in
HFI Connect - Hepatitis
9 years ago
State restrictions for hepatitis C drug may go too far
(Reuters Health) - State-run insurance programs for the poor may be putting up illegal barriers that prevent people with hepatitis C from getting a new treatment, a new study suggests. "We had this idea that there were restrictions in place, but we didn't anticipate the breadth of these restrictions
(Reuters Health) - State-run insurance programs for the poor may be putting up illegal barriers that prevent people with hepatitis C from getting a new treatment, a new study suggests. "We had this idea that there were restrictions in place, but we didn't anticipate the breadth of these restrictions
kcohen
in
HFI Connect - Hepatitis
9 years ago
State restrictions for hepatitis C drug may go too far
(Reuters Health) - State-run insurance programs for the poor may be putting up illegal barriers that prevent people with hepatitis C from getting a new treatment, a new study suggests. "We had this idea that there were restrictions in place, but we didn't anticipate the breadth of these restrictions
(Reuters Health) - State-run insurance programs for the poor may be putting up illegal barriers that prevent people with hepatitis C from getting a new treatment, a new study suggests. "We had this idea that there were restrictions in place, but we didn't anticipate the breadth of these restrictions
kcohen
in
HFI Connect - Hepatitis
9 years ago
California could spend nearly $5 billion on HCV drugs over next year
The wholesale acquisition cost price of $117,000 is based on the following regimens: 8, 12 and 24 weeks of Harvoni (
ledipasvir
/
sofosbuvir
, Gilead Sciences) and 12 and 24 weeks of Sovaldi (sofosbuvir, Gilead Sciences) plus ribavirin.
The wholesale acquisition cost price of $117,000 is based on the following regimens: 8, 12 and 24 weeks of Harvoni (
ledipasvir
/
sofosbuvir
, Gilead Sciences) and 12 and 24 weeks of Sovaldi (sofosbuvir, Gilead Sciences) plus ribavirin.
kcohen
in
HFI Connect - Hepatitis
9 years ago
WHO Adds New Hepatitis C Drugs to Essential Medicines List
Gilead’s combo drug Harvoni (
ledipasvir
/
sofosbuvir
) was put on the WHO’s “complementary list” for suggested HCV treatment. The WHO also added 16 new cancer drugs to its 2015 essential medicines list, as well as four new antibiotics designed to treat drug-resistant tuberculosis.
Gilead’s combo drug Harvoni (
ledipasvir
/
sofosbuvir
) was put on the WHO’s “complementary list” for suggested HCV treatment. The WHO also added 16 new cancer drugs to its 2015 essential medicines list, as well as four new antibiotics designed to treat drug-resistant tuberculosis.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
World Health Organization Throws Weight Behind Hep C Treatments
Included in the list are Gilead Sciences’ Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
Included in the list are Gilead Sciences’ Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Harvoni and Sovaldi/Daclatasvir Safer to Mix With HIV Meds
Gilead Sciences’ Harvoni (
ledipasvir
/
sofosbuvir
) and the combination of Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s as-yet-unapproved daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of HIV/hepatitis C virus (HCV) coinfected adults, the National
Gilead Sciences’ Harvoni (
ledipasvir
/
sofosbuvir
) and the combination of Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s as-yet-unapproved daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of HIV/hepatitis C virus (HCV) coinfected adults, the National
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
World Health Organization Throws Weight Behind Hep C Treatments
Included in the list are Gilead Sciences’ Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
Included in the list are Gilead Sciences’ Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Sanders Urges Veterans Affairs to Break Hepatitis C Patents
The politician wrote an open letter to the VA asking the agency to override patent protections held by Gilead Sciences for Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
) treatments, as well as patents held by AbbVie for its Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) combo regimen
The politician wrote an open letter to the VA asking the agency to override patent protections held by Gilead Sciences for Sovaldi (
sofosbuvir
) and Harvoni (
ledipasvir
/
sofosbuvir
) treatments, as well as patents held by AbbVie for its Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) combo regimen
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Harvoni Beats Hep C Among Those With Advanced Liver Disease
Gilead Sciences’ Harvoni (
ledipasvir
/
sofosbuvir
) and ribavirin cures hepatitis C virus (HCV) at mostly high rates among those with decompensated cirrhosis or who have had recurrent hep C after a liver transplant, MedPage Today reports.
Gilead Sciences’ Harvoni (
ledipasvir
/
sofosbuvir
) and ribavirin cures hepatitis C virus (HCV) at mostly high rates among those with decompensated cirrhosis or who have had recurrent hep C after a liver transplant, MedPage Today reports.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Harvoni Beats Hep C Among Those With Advanced Liver Disease
Gilead Sciences’ Harvoni (
ledipasvir
/
sofosbuvir
) and ribavirin cures hepatitis C virus (HCV) at mostly high rates among those with decompensated cirrhosis or who have had recurrent hep C after a liver transplant, MedPage Today reports.
Gilead Sciences’ Harvoni (
ledipasvir
/
sofosbuvir
) and ribavirin cures hepatitis C virus (HCV) at mostly high rates among those with decompensated cirrhosis or who have had recurrent hep C after a liver transplant, MedPage Today reports.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Patent for hepatitis C treatment would cut access for millions, groups say:
Activists charged the pharmaceutical company Gilead on Wednesday of seeking unjustified patents for a hepatitis C medication that would make the treatment prohibitively expensive for millions worldwide. The Initiative for Medicines, Access and Knowledge (I-MAK), a legal advocacy group, announced patent
Activists charged the pharmaceutical company Gilead on Wednesday of seeking unjustified patents for a hepatitis C medication that would make the treatment prohibitively expensive for millions worldwide. The Initiative for Medicines, Access and Knowledge (I-MAK), a legal advocacy group, announced patent
mwright
in
HFI Connect - Hepatitis
9 years ago
Sofosbuvir/Daclatasvir Combination Effective in Hepatitis C Treatment - See more at: http://www.specialtypharmacytimes.com/news/Sofosbuvir-D
he combination of sofosbuvir and daclatasvir showed promising results for the treatment of hepatitis C virus (HCV) during a recent clinical trial, which was the first to evaluate this drug combination in a real world setting. - See more at: http://www.specialtypharmacytimes.com/news/Sofosbuvir-Daclatasvir-Combination-Effective-in-Hepatitis-C-Treatment
he combination of sofosbuvir and daclatasvir showed promising results for the treatment of hepatitis C virus (HCV) during a recent clinical trial, which was the first to evaluate this drug combination in a real world setting. - See more at: http://www.specialtypharmacytimes.com/news/Sofosbuvir-Daclatasvir-Combination-Effective-in-Hepatitis-C-Treatment
mwright
in
HFI Connect - Hepatitis
9 years ago
FDA warns of cardiac reactions with Harvoni, Sovaldi drug combinations
The FDA approved the changes to the Harvoni (
ledipasvir
/
sofosbuvir
, Gilead Sciences) fixed- dose and Sovaldi (sofosbuvir) labels to update the Warnings and Precautions, Adverse Reactions and Drug Interactions sections, after nine serious cases of symptomatic bradycardia and one fatal cardiac arrest
The FDA approved the changes to the Harvoni (
ledipasvir
/
sofosbuvir
, Gilead Sciences) fixed- dose and Sovaldi (sofosbuvir) labels to update the Warnings and Precautions, Adverse Reactions and Drug Interactions sections, after nine serious cases of symptomatic bradycardia and one fatal cardiac arrest
mwright
in
HFI Connect - Hepatitis
10 years ago
Adverse side effects on Sofosbuvir and Ribavarin
Was wondering if anyone has had serious adverse side effects on Sofosbuvir and Ribavarin used to treat HepC and what support they had been offered? And also prior to treatment were they fully aware of the side effects? Thanks.
Was wondering if anyone has had serious adverse side effects on Sofosbuvir and Ribavarin used to treat HepC and what support they had been offered? And also prior to treatment were they fully aware of the side effects? Thanks.
cookiecrumbles
in
British Liver Trust
9 years ago
96% Hep C Cure Rate for Harvoni in Those Coinfected With HIV
Harvoni (
ledipasvir
/
sofosbuvir
) yielded a 96 percent cure rate among people with genotype 1 of hepatitis C virus (HCV), as well as a small number of those with genotype 4.
Harvoni (
ledipasvir
/
sofosbuvir
) yielded a 96 percent cure rate among people with genotype 1 of hepatitis C virus (HCV), as well as a small number of those with genotype 4.
mwright
in
HFI Connect - Hepatitis
10 years ago
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India
(Nasdaq: MYL) today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi® (
sofosbuvir
400mg tablets) and Harvoni®(
ledipasvir
90mg/
sofosbuvir
400 mg
(Nasdaq: MYL) today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi® (
sofosbuvir
400mg tablets) and Harvoni®(
ledipasvir
90mg/
sofosbuvir
400 mg
mwright
in
HFI Connect - Hepatitis
10 years ago
1
2
3
Next page
Filter results
Clear filters
Posted in
All communities
HFI Connect - Hepatitis
32 results
British Liver Trust
5 results
Hepatitis C Support
5 results
View top 10 communities
Sort by
Most Relevant
Newest